ES2602618T3 - Composiciones de fenilalanina amoníaco-liasa procariótica y métodos de tratamiento del cáncer que usan composiciones de la misma - Google Patents

Composiciones de fenilalanina amoníaco-liasa procariótica y métodos de tratamiento del cáncer que usan composiciones de la misma Download PDF

Info

Publication number
ES2602618T3
ES2602618T3 ES08795357.6T ES08795357T ES2602618T3 ES 2602618 T3 ES2602618 T3 ES 2602618T3 ES 08795357 T ES08795357 T ES 08795357T ES 2602618 T3 ES2602618 T3 ES 2602618T3
Authority
ES
Spain
Prior art keywords
avpal
pal
sequence
prokaryotic
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08795357.6T
Other languages
English (en)
Spanish (es)
Inventor
Michel C. Vellard
Paul A. Fitzpatrick
Emil D. Kakkis
Daniel J. Wendt
Mubarack Muthalif
Sean M. Bell
Augustus O. Okhamafe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40363135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2602618(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Application granted granted Critical
Publication of ES2602618T3 publication Critical patent/ES2602618T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES08795357.6T 2007-08-17 2008-08-15 Composiciones de fenilalanina amoníaco-liasa procariótica y métodos de tratamiento del cáncer que usan composiciones de la misma Active ES2602618T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6612507P 2007-08-17 2007-08-17
US66125P 2007-08-17
PCT/US2008/009765 WO2009025760A2 (en) 2007-08-17 2008-08-15 Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

Publications (1)

Publication Number Publication Date
ES2602618T3 true ES2602618T3 (es) 2017-02-21

Family

ID=40363135

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08795357.6T Active ES2602618T3 (es) 2007-08-17 2008-08-15 Composiciones de fenilalanina amoníaco-liasa procariótica y métodos de tratamiento del cáncer que usan composiciones de la misma

Country Status (23)

Country Link
US (4) US7537923B2 (enExample)
EP (1) EP2175875B1 (enExample)
JP (1) JP5584120B2 (enExample)
CN (1) CN101803492B (enExample)
AR (2) AR067972A1 (enExample)
AU (1) AU2008289549B2 (enExample)
BR (2) BR122018072594B8 (enExample)
CA (1) CA2687028C (enExample)
CL (1) CL2008002390A1 (enExample)
CY (1) CY1118222T1 (enExample)
DK (1) DK2175875T3 (enExample)
ES (1) ES2602618T3 (enExample)
HR (1) HRP20161474T1 (enExample)
HU (1) HUE029510T4 (enExample)
LT (1) LT2175875T (enExample)
MX (1) MX2009012261A (enExample)
PE (1) PE20090605A1 (enExample)
PL (1) PL2175875T3 (enExample)
PT (1) PT2175875T (enExample)
RU (2) RU2009141987A (enExample)
SI (1) SI2175875T1 (enExample)
TW (1) TWI418787B (enExample)
WO (1) WO2009025760A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
EP3381445B1 (en) 2007-11-15 2023-10-25 Amgen Inc. Aqueous formulation of antibody stablised by antioxidants for parenteral administration
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2011078667A2 (en) 2009-12-22 2011-06-30 Dsm Ip Assets B.V. Method of finding a biocatalyst having ammonia lyase activity
EP3025728B1 (en) * 2010-02-04 2018-08-08 BioMarin Pharmaceutical Inc. Method for purifying prokaryotic phenylalanine ammonia-lyase variants
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
US20150246083A1 (en) * 2012-07-27 2015-09-03 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
SMT201900315T1 (it) 2013-04-18 2019-07-11 Codexis Inc Polipeptidi di fenilalanina ammoniaca liasi ingegnerizzati
EP3071515A2 (en) 2013-11-18 2016-09-28 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
EP3583946A1 (en) 2014-04-01 2019-12-25 Rubius Therapeutics, Inc. Enucleated hematopoietic cells comprising an exogenous antigen
CA2943432A1 (en) 2014-04-16 2015-10-22 Codexis, Inc. Engineered tyrosine ammonia lyase
ES2897635T3 (es) 2014-04-29 2022-03-02 Bio Cancer Treat International Ltd Métodos y composiciones para modular el sistema inmunológico con la arginasa I
US10752923B2 (en) 2014-07-14 2020-08-25 Cysbio Aps Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity
US20170360900A1 (en) 2014-12-22 2017-12-21 Codexis, Inc. Human alpha-galactosidase variants
AU2017301600B2 (en) 2016-07-26 2022-08-04 Biomarin Pharmaceutical Inc. Novel adeno-associated virus capsid proteins
IT201600086488A1 (it) * 2016-08-22 2018-02-22 St Microelectronics Srl Dispositivo a semiconduttore e corrispondente procedimento
SG11201906880VA (en) * 2017-02-13 2019-08-27 Codexis Inc Engineered phenylalanine ammonia lyase polypeptides
CA3099704A1 (en) 2018-05-09 2019-11-14 Biomarin Pharmaceutical Inc. Methods of treating phenylketonuria
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
EP3807409A4 (en) 2018-06-12 2022-08-03 Codexis, Inc. Engineered tyrosine ammonia lyase
EP3893860A4 (en) 2018-12-14 2023-03-29 Codexis, Inc. ENGINEERED TYROSINE AMMONIA LYASE
MX2021007552A (es) 2018-12-20 2021-08-11 Codexis Inc Variantes de alfa-galactosidasa humana.
KR102884442B1 (ko) 2019-02-14 2025-11-10 솜 이노베이션 바이오테크, 에스.에이. 페닐케톤뇨증 치료에 사용하기 위한 트리암테렌 또는 놀라트렉세드
MX2022001515A (es) * 2019-08-07 2022-04-06 Rakuten Medical Inc Composiciones de conjugado de cetuximab-ir700.
MX2022002473A (es) 2019-08-30 2022-08-02 Codexis Inc Variantes de lipasa modificadas geneticamente.
PE20221266A1 (es) 2019-12-20 2022-08-16 Codexis Inc Variantes de alfa-glucosidasa acida disenadas por ingenieria
BR112022015139A2 (pt) 2020-02-04 2022-10-11 Codexis Inc Polipeptídeo da leucina descarboxilase engenheirada, composição, sequência de polinucleotídeo engenheirado, vetor de expressão, célula hospedeira, métodos para produzir um polipeptídeo da leucina descarboxilase engenheirada e para tratar e/ou prevenir os sintomas de doença da urina de xarope de bordo, composição, e, uso
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
CA3191867A1 (en) 2020-08-28 2022-03-03 Codexis, Inc. Engineered protease variants
WO2022047264A1 (en) 2020-08-28 2022-03-03 Codexis, Inc. Engineered amylase variants
EP4341394A4 (en) 2021-05-19 2025-04-09 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia lyase and methods for treating adolescent patients
AU2022279241A1 (en) 2021-05-21 2023-11-30 Syntis Bio, Inc. Engineered methionine gamma lyase variants
JP2024540358A (ja) 2021-11-01 2024-10-31 シンティス バイオ，インコーポレイティド 工学操作ロイシン脱炭酸酵素
CN115873837A (zh) * 2022-11-18 2023-03-31 安徽盈科生物科技有限公司 高表达的新型的苯丙氨酸解氨酶
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
TW202521161A (zh) 2023-11-17 2025-06-01 美商拜奧馬林製藥公司 苯丙胺酸解氨酶與ｐｏｅｇｍａ之結合物及其使用方法

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5212939A (en) * 1991-12-04 1993-05-25 Pratt Jr John M Marine mooring swivel fitting
ES2184756T3 (es) 1992-11-19 2003-04-16 Anticancer Inc Uso de metioninasa como agente antitumoral en quimioterapia antimetionina.
JP4007516B2 (ja) 1992-12-04 2007-11-14 ロバーツ，ジョゼフ 遺伝学的に操作されたグルタミナーゼ、および抗ウイルスと抗ガン治療におけるその使用
DK75593D0 (enExample) 1993-06-25 1993-06-25 Novo Nordisk As
KR0164757B1 (ko) * 1995-06-13 1999-01-15 김광호 공조장치의 살균집진장치와 그 방법
AU718439B2 (en) 1995-09-21 2000-04-13 Genentech Inc. Human growth hormone variants
CU22585A1 (es) 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
JP4812167B2 (ja) 1999-02-12 2011-11-09 モレキュラー インサイト ファーマスーティカルズ インコーポレイテッド 薬物輸送用マトリックス、ならびにその作成方法および使用方法
US6586398B1 (en) 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
CA2406390A1 (en) 2000-04-14 2001-10-25 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
US6939941B2 (en) * 2001-09-12 2005-09-06 Toray Fine Chemicals Co., Ltd. Preparation of polysulfide compositions
IL162811A0 (en) 2002-02-26 2005-11-20 Du Pont Method for the recombination of genetic elements
US20080124275A1 (en) 2002-11-14 2008-05-29 The Scripps Research Institute Crystalline Form of Fatty Acid Amide Hydrolase (Faah)
WO2006034373A2 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
DE102006032167B4 (de) 2006-07-12 2014-11-27 Evonik Degussa Gmbh Verfahren zur Herstellung von Triallylisocyanurat (TAIC)
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2010014225A2 (en) 2008-07-30 2010-02-04 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase

Also Published As

Publication number Publication date
SI2175875T1 (sl) 2017-01-31
US7537923B2 (en) 2009-05-26
BR122018072594B1 (pt) 2020-10-27
EP2175875A2 (en) 2010-04-21
HRP20161474T1 (hr) 2016-12-30
EP2175875B1 (en) 2016-10-05
RU2012134838A (ru) 2014-03-20
US7790433B2 (en) 2010-09-07
AR117389A2 (es) 2021-08-04
HUE029510T2 (hu) 2017-02-28
CA2687028A1 (en) 2009-02-26
US7560263B2 (en) 2009-07-14
AU2008289549A1 (en) 2009-02-26
JP5584120B2 (ja) 2014-09-03
PL2175875T3 (pl) 2017-04-28
CA2687028C (en) 2016-02-16
BRPI0811589B1 (pt) 2020-05-12
CL2008002390A1 (es) 2009-05-29
DK2175875T3 (en) 2016-11-21
BRPI0811589B8 (pt) 2021-05-25
AR067972A1 (es) 2009-10-28
CY1118222T1 (el) 2017-06-28
US20090263369A1 (en) 2009-10-22
MX2009012261A (es) 2010-03-15
CN101803492A (zh) 2010-08-11
PT2175875T (pt) 2016-11-21
TWI418787B (zh) 2013-12-11
AU2008289549B2 (en) 2014-02-06
CN101803492B (zh) 2014-05-07
US20100278802A1 (en) 2010-11-04
WO2009025760A2 (en) 2009-02-26
JP2010536759A (ja) 2010-12-02
HUE029510T4 (en) 2017-05-29
BR122018072594B8 (pt) 2021-07-27
PE20090605A1 (es) 2009-05-16
WO2009025760A3 (en) 2009-06-25
TW200911283A (en) 2009-03-16
LT2175875T (lt) 2016-12-12
US20090047265A1 (en) 2009-02-19
BRPI0811589A2 (pt) 2014-10-29
US20090047268A1 (en) 2009-02-19
RU2009141987A (ru) 2011-05-20
RU2553343C2 (ru) 2015-06-10

Similar Documents

Publication Publication Date Title
BR122018072594B1 (pt) uso de uma composição farmacêutica
KR20130009761A (ko) 메티오닌-감마-라이아제 효소를 이용하여 유전자조작된 효소 및 이의 약리학적 제제
CN1264388A (zh) 多拉司他汀15衍生物
US6251388B1 (en) Utilization of Wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
ES2965372T3 (es) Variantes de L-asparaginasa de cobaya truncada y métodos de uso
JP2022545916A (ja) コンプスタチン類似体及びその医学的使用
WO2021156504A1 (en) Treatment of panx1 associates diseases
US20020137684A1 (en) Ligand for enhancing oral and CNS delivery of biological agents
CN102140473A (zh) 抗肿瘤的核酸与多肽及其应用
JPH01316400A (ja) 修飾ポリペプチド
WO2019136139A2 (en) Antimicrobial peptides and use thereof
CN110117324B (zh) 一种抗肿瘤活性多肽及其用途
AU2017214761B2 (en) Proteinaceous compounds and uses therefor
US9815867B2 (en) Peptide for inhibiting vascular endothelial growth factor receptor
JP2018520131A (ja) 新規ペプチド及びその用途
JP5353111B2 (ja) Ｓａｒｓ３ｃｌプロテアーゼの組換えタンパク質
JP2004514410A5 (enExample)
EP1385873A2 (en) A ligand for enhancing oral and cns delivery of biological agents
TW202606749A (zh) 一種多肽化合物及其製備方法和應用
US6991788B1 (en) Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
EP1219706A2 (en) Production processes for recombinant wolinella succinogenes asparaginase
IL323710A (en) Extremely minimal inverted terminal repeats (ITR) sequences and their uses
WO2010038010A1 (en) Somatostatin analogues
Chan Development of recombinant human augmenter of liver regeneration (ALR) for treatment of liver diseases
HK1159179A (en) Anti-tumor nucleic acids and polypeptides and use thereof